nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—Fluoxymesterone—breast cancer	0.272	1	CrCtD
Medroxyprogesterone Acetate—PGR—breast cancer	0.0497	0.27	CbGaD
Medroxyprogesterone Acetate—SHBG—breast cancer	0.0464	0.252	CbGaD
Medroxyprogesterone Acetate—AR—breast cancer	0.0407	0.221	CbGaD
Medroxyprogesterone Acetate—ESR1—breast cancer	0.0314	0.17	CbGaD
Medroxyprogesterone Acetate—SHBG—Fluoxymesterone—breast cancer	0.0306	0.14	CbGbCtD
Medroxyprogesterone Acetate—AR—Fluoxymesterone—breast cancer	0.0256	0.117	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Fluoxymesterone—breast cancer	0.0221	0.101	CbGbCtD
Medroxyprogesterone Acetate—ESR1—Toremifene—breast cancer	0.0221	0.101	CbGbCtD
Medroxyprogesterone Acetate—Dydrogesterone—Exemestane—breast cancer	0.0206	0.109	CrCrCtD
Medroxyprogesterone Acetate—ESR1—Fulvestrant—breast cancer	0.0205	0.0942	CbGbCtD
Medroxyprogesterone Acetate—Eplerenone—Fluoxymesterone—breast cancer	0.018	0.0953	CrCrCtD
Medroxyprogesterone Acetate—NR3C1—Fluoxymesterone—breast cancer	0.0163	0.0746	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—breast cancer	0.016	0.0869	CbGaD
Medroxyprogesterone Acetate—Dydrogesterone—Fluoxymesterone—breast cancer	0.0143	0.0757	CrCrCtD
Medroxyprogesterone Acetate—Spironolactone—Fluoxymesterone—breast cancer	0.0136	0.0721	CrCrCtD
Medroxyprogesterone Acetate—Potassium Canrenoate—Fluoxymesterone—breast cancer	0.0136	0.0721	CrCrCtD
Medroxyprogesterone Acetate—Megestrol acetate—Fluoxymesterone—breast cancer	0.0124	0.066	CrCrCtD
Medroxyprogesterone Acetate—ESR1—Raloxifene—breast cancer	0.0122	0.056	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—breast cancer	0.0108	0.0497	CbGbCtD
Medroxyprogesterone Acetate—Methylprednisolone—Exemestane—breast cancer	0.0105	0.0558	CrCrCtD
Medroxyprogesterone Acetate—Testosterone—Exemestane—breast cancer	0.0105	0.0558	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortamate—Fluoxymesterone—breast cancer	0.00998	0.053	CrCrCtD
Medroxyprogesterone Acetate—Cortisone acetate—Fluoxymesterone—breast cancer	0.00967	0.0513	CrCrCtD
Medroxyprogesterone Acetate—Progesterone—Fluoxymesterone—breast cancer	0.0084	0.0446	CrCrCtD
Medroxyprogesterone Acetate—Testosterone Propionate—Fluoxymesterone—breast cancer	0.0084	0.0446	CrCrCtD
Medroxyprogesterone Acetate—Fludrocortisone—Fluoxymesterone—breast cancer	0.0084	0.0446	CrCrCtD
Medroxyprogesterone Acetate—Methyltestosterone—Fluoxymesterone—breast cancer	0.00819	0.0435	CrCrCtD
Medroxyprogesterone Acetate—ESR1—Tamoxifen—breast cancer	0.00807	0.037	CbGbCtD
Medroxyprogesterone Acetate—Fluorometholone—Fluoxymesterone—breast cancer	0.0078	0.0414	CrCrCtD
Medroxyprogesterone Acetate—Testosterone—Fluoxymesterone—breast cancer	0.00729	0.0387	CrCrCtD
Medroxyprogesterone Acetate—Hydrocortisone—Fluoxymesterone—breast cancer	0.00685	0.0364	CrCrCtD
Medroxyprogesterone Acetate—CYP2C9—Anastrozole—breast cancer	0.00427	0.0196	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Lapatinib—breast cancer	0.00408	0.0187	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Exemestane—breast cancer	0.00327	0.015	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Idarubicin—breast cancer	0.00323	0.0148	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Raloxifene—breast cancer	0.00309	0.0142	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Letrozole—breast cancer	0.00278	0.0128	CbGbCtD
Medroxyprogesterone Acetate—PGR—corpus luteum—breast cancer	0.00265	0.139	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Anastrozole—breast cancer	0.00248	0.0114	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Toremifene—breast cancer	0.00227	0.0104	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Fulvestrant—breast cancer	0.00211	0.00967	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Tamoxifen—breast cancer	0.00204	0.00937	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Thiotepa—breast cancer	0.00188	0.00862	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Capecitabine—breast cancer	0.00177	0.00813	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Ixabepilone—breast cancer	0.00172	0.00789	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Lapatinib—breast cancer	0.00166	0.00759	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Paclitaxel—breast cancer	0.00159	0.0073	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Fluorouracil—breast cancer	0.00151	0.00691	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Tamoxifen—breast cancer	0.00143	0.00654	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Raloxifene—breast cancer	0.00125	0.00575	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Paclitaxel—breast cancer	0.00111	0.00509	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Fluorouracil—breast cancer	0.00105	0.00482	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vinorelbine—breast cancer	0.000918	0.00421	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Tamoxifen—breast cancer	0.000829	0.0038	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Mitoxantrone—breast cancer	0.000808	0.00371	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—pituitary gland—breast cancer	0.00065	0.034	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Paclitaxel—breast cancer	0.000645	0.00296	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Irinotecan—breast cancer	0.000636	0.00292	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—female reproductive system—breast cancer	0.000595	0.0311	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—adrenal gland—breast cancer	0.00058	0.0304	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Vinblastine—breast cancer	0.000566	0.0026	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—female gonad—breast cancer	0.000541	0.0283	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—endocrine gland—breast cancer	0.000503	0.0263	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—nipple—breast cancer	0.000502	0.0262	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Docetaxel—breast cancer	0.000466	0.00214	CbGbCtD
Medroxyprogesterone Acetate—PGR—mammary gland—breast cancer	0.000411	0.0215	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vincristine—Vinorelbine—breast cancer	0.000351	0.384	CbGdCrCtD
Medroxyprogesterone Acetate—HSD3B2—lymph node—breast cancer	0.000348	0.0182	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—breast cancer	0.000348	0.00159	CbGbCtD
Medroxyprogesterone Acetate—PGR—nipple—breast cancer	0.00034	0.0178	CbGeAlD
Medroxyprogesterone Acetate—ESR1—mammary gland—breast cancer	0.000321	0.0168	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—endometrium—breast cancer	0.000303	0.0158	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vinorelbine—breast cancer	0.000282	0.309	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—Vincristine—Vinblastine—breast cancer	0.000281	0.307	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—uterus—breast cancer	0.000279	0.0146	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—pituitary gland—breast cancer	0.000274	0.0143	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—adipose tissue—breast cancer	0.000273	0.0143	CbGeAlD
Medroxyprogesterone Acetate—AR—nipple—breast cancer	0.000271	0.0142	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—mammary gland—breast cancer	0.000265	0.0138	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—adrenal gland—breast cancer	0.000245	0.0128	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—bone marrow—breast cancer	0.000237	0.0124	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—mammary gland—breast cancer	0.000235	0.0123	CbGeAlD
Medroxyprogesterone Acetate—Fluoxymesterone—PRLR—breast cancer	0.000229	0.128	CrCbGaD
Medroxyprogesterone Acetate—PGR—epithelium—breast cancer	0.000229	0.012	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—female gonad—breast cancer	0.000228	0.0119	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endometrium—breast cancer	0.000228	0.0119	CbGeAlD
Medroxyprogesterone Acetate—ESR1—embryo—breast cancer	0.000219	0.0115	CbGeAlD
Medroxyprogesterone Acetate—SHBG—uterus—breast cancer	0.00021	0.011	CbGeAlD
Medroxyprogesterone Acetate—SHBG—pituitary gland—breast cancer	0.000206	0.0108	CbGeAlD
Medroxyprogesterone Acetate—SHBG—adipose tissue—breast cancer	0.000205	0.0107	CbGeAlD
Medroxyprogesterone Acetate—PGR—endometrium—breast cancer	0.000205	0.0107	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—nipple—breast cancer	0.000196	0.0103	CbGeAlD
Medroxyprogesterone Acetate—PGR—uterus—breast cancer	0.000189	0.00989	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female reproductive system—breast cancer	0.000189	0.00987	CbGeAlD
Medroxyprogesterone Acetate—PGR—pituitary gland—breast cancer	0.000186	0.00971	CbGeAlD
Medroxyprogesterone Acetate—PGR—adipose tissue—breast cancer	0.000185	0.00967	CbGeAlD
Medroxyprogesterone Acetate—SHBG—adrenal gland—breast cancer	0.000184	0.00963	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—breast cancer	0.000182	0.00953	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—breast cancer	0.000179	0.00936	CbGeAlD
Medroxyprogesterone Acetate—SHBG—bone marrow—breast cancer	0.000178	0.00932	CbGeAlD
Medroxyprogesterone Acetate—AR—skin of body—breast cancer	0.000173	0.00907	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—breast cancer	0.000172	0.00898	CbGeAlD
Medroxyprogesterone Acetate—PGR—female reproductive system—breast cancer	0.00017	0.00889	CbGeAlD
Medroxyprogesterone Acetate—PGR—adrenal gland—breast cancer	0.000166	0.00867	CbGeAlD
Medroxyprogesterone Acetate—AR—endometrium—breast cancer	0.000163	0.00855	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—embryo—breast cancer	0.000162	0.00846	CbGeAlD
Medroxyprogesterone Acetate—ESR1—endometrium—breast cancer	0.00016	0.00839	CbGeAlD
Medroxyprogesterone Acetate—SHBG—endocrine gland—breast cancer	0.00016	0.00835	CbGeAlD
Medroxyprogesterone Acetate—PGR—female gonad—breast cancer	0.000155	0.00809	CbGeAlD
Medroxyprogesterone Acetate—AR—uterus—breast cancer	0.000151	0.00788	CbGeAlD
Medroxyprogesterone Acetate—AR—pituitary gland—breast cancer	0.000148	0.00774	CbGeAlD
Medroxyprogesterone Acetate—ESR1—uterus—breast cancer	0.000148	0.00773	CbGeAlD
Medroxyprogesterone Acetate—AR—adipose tissue—breast cancer	0.000147	0.0077	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—breast cancer	0.000147	0.00768	CbGeAlD
Medroxyprogesterone Acetate—ESR1—pituitary gland—breast cancer	0.000145	0.00759	CbGeAlD
Medroxyprogesterone Acetate—ESR1—adipose tissue—breast cancer	0.000145	0.00756	CbGeAlD
Medroxyprogesterone Acetate—PGR—endocrine gland—breast cancer	0.000144	0.00752	CbGeAlD
Medroxyprogesterone Acetate—AR—female reproductive system—breast cancer	0.000135	0.00708	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female reproductive system—breast cancer	0.000133	0.00695	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—endometrium—breast cancer	0.000132	0.00691	CbGeAlD
Medroxyprogesterone Acetate—AR—adrenal gland—breast cancer	0.000132	0.00691	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—breast cancer	0.000132	0.0069	CbGeAlD
Medroxyprogesterone Acetate—ESR1—adrenal gland—breast cancer	0.00013	0.00678	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—skin of body—breast cancer	0.000126	0.00657	CbGeAlD
Medroxyprogesterone Acetate—AR—female gonad—breast cancer	0.000123	0.00644	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female gonad—breast cancer	0.000121	0.00633	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—pituitary gland—breast cancer	0.00012	0.00626	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—endometrium—breast cancer	0.000118	0.00619	CbGeAlD
Medroxyprogesterone Acetate—AR—endocrine gland—breast cancer	0.000115	0.00599	CbGeAlD
Medroxyprogesterone Acetate—ESR1—endocrine gland—breast cancer	0.000112	0.00588	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—female reproductive system—breast cancer	0.000109	0.00573	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—uterus—breast cancer	0.000109	0.00571	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—pituitary gland—breast cancer	0.000107	0.0056	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—adipose tissue—breast cancer	0.000107	0.00558	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—AR—breast cancer	0.000102	0.0573	CrCbGaD
Medroxyprogesterone Acetate—PGR—lymph node—breast cancer	9.94e-05	0.0052	CbGeAlD
Medroxyprogesterone Acetate—Dydrogesterone—PGR—breast cancer	9.93e-05	0.0555	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—female reproductive system—breast cancer	9.81e-05	0.00513	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—female reproductive system—breast cancer	9.73e-05	0.00509	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—adrenal gland—breast cancer	9.57e-05	0.00501	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—endocrine gland—breast cancer	9.27e-05	0.00485	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bone marrow—breast cancer	9.26e-05	0.00484	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female gonad—breast cancer	8.92e-05	0.00467	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—CYP19A1—breast cancer	8.58e-05	0.0479	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—endocrine gland—breast cancer	8.3e-05	0.00434	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—endocrine gland—breast cancer	8.23e-05	0.0043	CbGeAlD
Medroxyprogesterone Acetate—Ethynodiol—PGR—breast cancer	8.18e-05	0.0457	CrCbGaD
Medroxyprogesterone Acetate—AR—lymph node—breast cancer	7.92e-05	0.00414	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—breast cancer	7.78e-05	0.00407	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—female reproductive system—breast cancer	7.42e-05	0.00388	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—endocrine gland—breast cancer	6.28e-05	0.00328	CbGeAlD
Medroxyprogesterone Acetate—Megestrol acetate—PGR—breast cancer	5.97e-05	0.0334	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—CYP17A1—breast cancer	5.9e-05	0.033	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—breast cancer	5.74e-05	0.003	CbGeAlD
Medroxyprogesterone Acetate—Drospirenone—PGR—breast cancer	5.22e-05	0.0292	CrCbGaD
Medroxyprogesterone Acetate—Ethynodiol—ESR1—breast cancer	5.16e-05	0.0289	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—COMT—breast cancer	4.81e-05	0.0269	CrCbGaD
Medroxyprogesterone Acetate—Drospirenone—AR—breast cancer	4.28e-05	0.0239	CrCbGaD
Medroxyprogesterone Acetate—Fludrocortisone—AR—breast cancer	4.03e-05	0.0225	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—SHBG—breast cancer	3.79e-05	0.0212	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—PGR—breast cancer	3.71e-05	0.0208	CrCbGaD
Medroxyprogesterone Acetate—Testosterone Propionate—AR—breast cancer	3.59e-05	0.0201	CrCbGaD
Medroxyprogesterone Acetate—Drospirenone—BCHE—breast cancer	3.57e-05	0.02	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—SHBG—breast cancer	3.47e-05	0.0194	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—AR—breast cancer	3.32e-05	0.0186	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—SHBG—breast cancer	3.06e-05	0.0171	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—AR—breast cancer	3.04e-05	0.017	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP17A1—breast cancer	2.71e-05	0.0151	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—AR—breast cancer	2.68e-05	0.015	CrCbGaD
Medroxyprogesterone Acetate—Fluoxymesterone—ESR1—breast cancer	2.56e-05	0.0143	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ABCC1—breast cancer	2.46e-05	0.0137	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—SHBG—breast cancer	2.31e-05	0.0129	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP19A1—breast cancer	2.25e-05	0.0126	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortamate—CYP3A4—breast cancer	2.03e-05	0.0113	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—PGR—breast cancer	2.01e-05	0.0112	CrCbGaD
Medroxyprogesterone Acetate—Cortisone acetate—CYP3A4—breast cancer	2e-05	0.0112	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—SHBG—breast cancer	1.88e-05	0.0105	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1B1—breast cancer	1.88e-05	0.0105	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—SHBG—breast cancer	1.78e-05	0.00993	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1B1—breast cancer	1.78e-05	0.00993	CrCbGaD
Medroxyprogesterone Acetate—Eplerenone—CYP3A4—breast cancer	1.75e-05	0.0098	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—AR—breast cancer	1.65e-05	0.00921	CrCbGaD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—breast cancer	1.65e-05	0.0092	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—ABCB1—breast cancer	1.6e-05	0.00896	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—ABCG2—breast cancer	1.59e-05	0.00889	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—AR—breast cancer	1.56e-05	0.0087	CrCbGaD
Medroxyprogesterone Acetate—Fluorometholone—CYP3A4—breast cancer	1.53e-05	0.00852	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—CYP3A4—breast cancer	1.47e-05	0.00824	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP19A1—breast cancer	1.3e-05	0.00729	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—ESR1—breast cancer	1.27e-05	0.00709	CrCbGaD
Medroxyprogesterone Acetate—Methylprednisolone—ABCB1—breast cancer	1.23e-05	0.00686	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—ABCG2—breast cancer	1.22e-05	0.00684	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP3A4—breast cancer	1.06e-05	0.0059	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP1A1—breast cancer	1.01e-05	0.00567	CrCbGaD
Medroxyprogesterone Acetate—Spironolactone—ABCB1—breast cancer	9.96e-06	0.00557	CrCbGaD
Medroxyprogesterone Acetate—Testosterone—CYP1A1—breast cancer	9.59e-06	0.00536	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—ALB—breast cancer	9.21e-06	0.00515	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—CYP3A4—breast cancer	7.95e-06	0.00444	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP2D6—breast cancer	7.55e-06	0.00422	CrCbGaD
Medroxyprogesterone Acetate—Hydrocortisone—ABCB1—breast cancer	6.62e-06	0.0037	CrCbGaD
Medroxyprogesterone Acetate—Progesterone—CYP3A4—breast cancer	6.48e-06	0.00362	CrCbGaD
Medroxyprogesterone Acetate—Dyspepsia—Docetaxel—breast cancer	6.31e-06	8.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—breast cancer	6.3e-06	8.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—breast cancer	6.3e-06	8.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Capecitabine—breast cancer	6.28e-06	8.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Fluorouracil—breast cancer	6.26e-06	8.55e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Fluorouracil—breast cancer	6.26e-06	8.54e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—breast cancer	6.25e-06	8.53e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Capecitabine—breast cancer	6.23e-06	8.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Docetaxel—breast cancer	6.23e-06	8.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Paclitaxel—breast cancer	6.23e-06	8.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Fluorouracil—breast cancer	6.22e-06	8.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—breast cancer	6.22e-06	8.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—breast cancer	6.2e-06	8.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—breast cancer	6.2e-06	8.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Docetaxel—breast cancer	6.19e-06	8.45e-05	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—breast cancer	6.19e-06	8.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Capecitabine—breast cancer	6.19e-06	8.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Docetaxel—breast cancer	6.18e-06	8.43e-05	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—breast cancer	6.17e-06	8.43e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—breast cancer	6.17e-06	8.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Irinotecan—breast cancer	6.16e-06	8.41e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Mitoxantrone—breast cancer	6.16e-06	8.41e-05	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—breast cancer	6.15e-06	8.39e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—breast cancer	6.13e-06	8.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Docetaxel—breast cancer	6.13e-06	8.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—breast cancer	6.12e-06	8.36e-05	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—CYP3A4—breast cancer	6.12e-06	0.00342	CrCbGaD
Medroxyprogesterone Acetate—Dyspepsia—Capecitabine—breast cancer	6.11e-06	8.34e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—breast cancer	6.11e-06	8.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—breast cancer	6.07e-06	8.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Paclitaxel—breast cancer	6.07e-06	8.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Capecitabine—breast cancer	6.03e-06	8.23e-05	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—breast cancer	6.01e-06	8.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Gemcitabine—breast cancer	6e-06	8.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Capecitabine—breast cancer	5.99e-06	8.18e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Capecitabine—breast cancer	5.98e-06	8.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Paclitaxel—breast cancer	5.98e-06	8.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—breast cancer	5.96e-06	8.14e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—breast cancer	5.95e-06	8.12e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Capecitabine—breast cancer	5.93e-06	8.1e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—breast cancer	5.92e-06	8.08e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—breast cancer	5.92e-06	8.08e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Docetaxel—breast cancer	5.91e-06	8.06e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Fluorouracil—breast cancer	5.9e-06	8.05e-05	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—breast cancer	5.88e-06	8.03e-05	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—breast cancer	5.87e-06	8.02e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—breast cancer	5.87e-06	8.01e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Docetaxel—breast cancer	5.86e-06	8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—breast cancer	5.85e-06	7.98e-05	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—breast cancer	5.84e-06	7.98e-05	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—breast cancer	5.84e-06	7.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—breast cancer	5.81e-06	7.93e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—breast cancer	5.8e-06	7.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Paclitaxel—breast cancer	5.79e-06	7.9e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—breast cancer	5.75e-06	7.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—breast cancer	5.73e-06	7.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Capecitabine—breast cancer	5.72e-06	7.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—breast cancer	5.71e-06	7.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—breast cancer	5.71e-06	7.79e-05	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—breast cancer	5.7e-06	7.77e-05	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—breast cancer	5.69e-06	7.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—breast cancer	5.69e-06	7.76e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Capecitabine—breast cancer	5.67e-06	7.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—breast cancer	5.67e-06	7.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Docetaxel—breast cancer	5.67e-06	7.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Docetaxel—breast cancer	5.67e-06	7.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—breast cancer	5.65e-06	7.71e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Paclitaxel—breast cancer	5.59e-06	7.63e-05	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—breast cancer	5.56e-06	7.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—breast cancer	5.52e-06	7.53e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Capecitabine—breast cancer	5.51e-06	7.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—breast cancer	5.5e-06	7.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Capecitabine—breast cancer	5.49e-06	7.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Capecitabine—breast cancer	5.49e-06	7.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—breast cancer	5.48e-06	7.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—breast cancer	5.48e-06	7.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—breast cancer	5.48e-06	7.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—breast cancer	5.48e-06	7.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—breast cancer	5.44e-06	7.43e-05	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—breast cancer	5.4e-06	7.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—ABCB1—breast cancer	5.39e-06	0.00301	CrCbGaD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—breast cancer	5.39e-06	7.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—breast cancer	5.39e-06	7.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—breast cancer	5.39e-06	7.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—breast cancer	5.38e-06	7.34e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Paclitaxel—breast cancer	5.38e-06	7.34e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—breast cancer	5.37e-06	7.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	5.35e-06	7.3e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—breast cancer	5.34e-06	7.29e-05	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ALB—breast cancer	5.34e-06	0.00298	CrCbGaD
Medroxyprogesterone Acetate—Rash—Paclitaxel—breast cancer	5.33e-06	7.28e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Paclitaxel—breast cancer	5.33e-06	7.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—breast cancer	5.32e-06	7.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—breast cancer	5.32e-06	7.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—breast cancer	5.32e-06	7.26e-05	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—breast cancer	5.31e-06	7.25e-05	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—breast cancer	5.3e-06	7.24e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Paclitaxel—breast cancer	5.3e-06	7.23e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Docetaxel—breast cancer	5.28e-06	7.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—breast cancer	5.27e-06	7.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—breast cancer	5.23e-06	7.14e-05	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—breast cancer	5.21e-06	7.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—breast cancer	5.21e-06	7.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—breast cancer	5.17e-06	7.05e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Docetaxel—breast cancer	5.14e-06	7.02e-05	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—breast cancer	5.13e-06	7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—breast cancer	5.13e-06	7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Capecitabine—breast cancer	5.11e-06	6.98e-05	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ABCB1—breast cancer	5.1e-06	0.00285	CrCbGaD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—breast cancer	5.09e-06	6.94e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Docetaxel—breast cancer	5.07e-06	6.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—breast cancer	5.07e-06	6.91e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—breast cancer	5.07e-06	6.91e-05	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—breast cancer	5.06e-06	6.9e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—breast cancer	5.04e-06	6.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—breast cancer	5.04e-06	6.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—breast cancer	5.04e-06	6.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—breast cancer	5.04e-06	6.87e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—breast cancer	5.03e-06	6.86e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Paclitaxel—breast cancer	5.02e-06	6.86e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—breast cancer	5.02e-06	6.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	5.01e-06	6.84e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—breast cancer	4.99e-06	6.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—breast cancer	4.98e-06	6.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Capecitabine—breast cancer	4.98e-06	6.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—breast cancer	4.94e-06	6.75e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—breast cancer	4.93e-06	6.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—breast cancer	4.92e-06	6.72e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—breast cancer	4.92e-06	6.72e-05	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—breast cancer	4.92e-06	6.71e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Capecitabine—breast cancer	4.91e-06	6.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Docetaxel—breast cancer	4.9e-06	6.69e-05	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—breast cancer	4.87e-06	6.65e-05	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—breast cancer	4.84e-06	6.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—breast cancer	4.83e-06	6.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—breast cancer	4.83e-06	6.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—breast cancer	4.83e-06	6.59e-05	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—breast cancer	4.82e-06	6.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—breast cancer	4.8e-06	6.55e-05	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—breast cancer	4.76e-06	6.49e-05	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—breast cancer	4.75e-06	6.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Capecitabine—breast cancer	4.75e-06	6.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—breast cancer	4.74e-06	6.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Docetaxel—breast cancer	4.74e-06	6.47e-05	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—breast cancer	4.73e-06	6.46e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—breast cancer	4.72e-06	6.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—breast cancer	4.71e-06	6.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—breast cancer	4.7e-06	6.41e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—breast cancer	4.67e-06	6.38e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—breast cancer	4.67e-06	6.38e-05	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—breast cancer	4.67e-06	6.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—breast cancer	4.67e-06	6.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—breast cancer	4.67e-06	6.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—breast cancer	4.65e-06	6.35e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—breast cancer	4.64e-06	6.33e-05	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	4.63e-06	6.32e-05	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—breast cancer	4.61e-06	6.29e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—breast cancer	4.61e-06	6.29e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—breast cancer	4.61e-06	6.29e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—breast cancer	4.59e-06	6.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Capecitabine—breast cancer	4.59e-06	6.26e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—breast cancer	4.56e-06	6.23e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Docetaxel—breast cancer	4.56e-06	6.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—breast cancer	4.55e-06	6.21e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Docetaxel—breast cancer	4.52e-06	6.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—breast cancer	4.52e-06	6.17e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Docetaxel—breast cancer	4.52e-06	6.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—breast cancer	4.51e-06	6.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—breast cancer	4.49e-06	6.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Docetaxel—breast cancer	4.49e-06	6.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—breast cancer	4.47e-06	6.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—breast cancer	4.47e-06	6.11e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—breast cancer	4.46e-06	6.09e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—breast cancer	4.45e-06	6.08e-05	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—breast cancer	4.44e-06	6.07e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Capecitabine—breast cancer	4.41e-06	6.02e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—breast cancer	4.4e-06	6.01e-05	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—breast cancer	4.4e-06	6.01e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—breast cancer	4.39e-06	5.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—breast cancer	4.38e-06	5.98e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Capecitabine—breast cancer	4.38e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—breast cancer	4.37e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Capecitabine—breast cancer	4.37e-06	5.97e-05	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—breast cancer	4.37e-06	5.96e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Capecitabine—breast cancer	4.35e-06	5.93e-05	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—breast cancer	4.34e-06	5.93e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—breast cancer	4.34e-06	5.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—breast cancer	4.32e-06	5.9e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—breast cancer	4.31e-06	5.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—breast cancer	4.3e-06	5.87e-05	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—breast cancer	4.26e-06	5.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Docetaxel—breast cancer	4.26e-06	5.81e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—breast cancer	4.26e-06	5.81e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—breast cancer	4.26e-06	5.81e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—breast cancer	4.22e-06	5.77e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—breast cancer	4.2e-06	5.74e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—breast cancer	4.18e-06	5.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—breast cancer	4.17e-06	5.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—breast cancer	4.17e-06	5.69e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—breast cancer	4.13e-06	5.64e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Capecitabine—breast cancer	4.12e-06	5.63e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—breast cancer	4.1e-06	5.6e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—breast cancer	4.08e-06	5.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—breast cancer	4.08e-06	5.57e-05	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—breast cancer	4.08e-06	5.56e-05	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—breast cancer	4.05e-06	5.52e-05	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—breast cancer	4.02e-06	5.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—breast cancer	3.99e-06	5.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—breast cancer	3.98e-06	5.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—breast cancer	3.98e-06	5.43e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—breast cancer	3.95e-06	5.4e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—breast cancer	3.94e-06	5.37e-05	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—breast cancer	3.89e-06	5.31e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—breast cancer	3.86e-06	5.27e-05	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—breast cancer	3.86e-06	5.26e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—breast cancer	3.84e-06	5.24e-05	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—breast cancer	3.83e-06	5.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—breast cancer	3.82e-06	5.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—breast cancer	3.82e-06	5.22e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—breast cancer	3.81e-06	5.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—breast cancer	3.71e-06	5.06e-05	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—breast cancer	3.69e-06	5.03e-05	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—breast cancer	3.66e-06	4.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—breast cancer	3.65e-06	4.99e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—breast cancer	3.56e-06	4.86e-05	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—breast cancer	3.55e-06	4.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—breast cancer	3.54e-06	4.83e-05	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—breast cancer	3.54e-06	4.83e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—breast cancer	3.53e-06	4.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—breast cancer	3.47e-06	4.73e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—breast cancer	3.42e-06	4.67e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—breast cancer	3.42e-06	4.66e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—breast cancer	3.31e-06	4.51e-05	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—breast cancer	3.3e-06	4.5e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—breast cancer	3.28e-06	4.48e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—breast cancer	3.26e-06	4.45e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—breast cancer	3.25e-06	4.44e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—breast cancer	3.24e-06	4.42e-05	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—breast cancer	3.21e-06	4.38e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—breast cancer	3.2e-06	4.36e-05	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—breast cancer	3.16e-06	4.32e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—breast cancer	3.07e-06	4.2e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Methotrexate—breast cancer	3.07e-06	4.19e-05	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—breast cancer	3.06e-06	4.18e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—breast cancer	3.05e-06	4.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—breast cancer	3.05e-06	4.16e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—breast cancer	3.03e-06	4.13e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—breast cancer	2.96e-06	4.04e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Epirubicin—breast cancer	2.87e-06	3.92e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—breast cancer	2.84e-06	3.88e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—breast cancer	2.82e-06	3.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—breast cancer	2.82e-06	3.85e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—breast cancer	2.8e-06	3.82e-05	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—breast cancer	2.66e-06	3.63e-05	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—E2F1—breast cancer	1.11e-06	2.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VEGFA—breast cancer	1.1e-06	2.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HPGDS—breast cancer	1.1e-06	2.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HBA1—breast cancer	1.09e-06	2.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STAT3—breast cancer	1.09e-06	2.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC2A1—breast cancer	1.09e-06	2.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NQO1—breast cancer	1.09e-06	2.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—IL6—breast cancer	1.09e-06	2.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL8—breast cancer	1.07e-06	2.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SPP1—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA3—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HMMR—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCC1—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ACHE—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTT1—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.07e-06	2.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP3A4—breast cancer	1.06e-06	2.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB3—breast cancer	1.06e-06	2.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.06e-06	2.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR2—breast cancer	1.06e-06	2.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1B—breast cancer	1.05e-06	2.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1B1—breast cancer	1.04e-06	2.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MAPK3—breast cancer	1.04e-06	2.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPARGC1B—breast cancer	1.03e-06	2.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—breast cancer	1.03e-06	2.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—breast cancer	1.03e-06	2.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HSP90AA1—breast cancer	1.02e-06	2.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL2—breast cancer	1.02e-06	2.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—breast cancer	1.01e-06	2.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TERT—breast cancer	1.01e-06	2.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TGFB1—breast cancer	1.01e-06	2.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP17A1—breast cancer	1.01e-06	2.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—breast cancer	1.01e-06	2.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS1—breast cancer	1e-06	2.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO1—breast cancer	1e-06	2.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—breast cancer	9.98e-07	2.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NCOA1—breast cancer	9.97e-07	2.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	9.96e-07	2.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—JUN—breast cancer	9.96e-07	2.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—breast cancer	9.93e-07	2.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNB1—breast cancer	9.88e-07	2.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR1—breast cancer	9.84e-07	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	9.84e-07	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—STK11—breast cancer	9.82e-07	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP19A1—breast cancer	9.82e-07	2.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2D6—breast cancer	9.81e-07	2.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA4—breast cancer	9.76e-07	2.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA9—breast cancer	9.76e-07	2.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HIF1A—breast cancer	9.69e-07	2.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MMP9—breast cancer	9.69e-07	2.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1A—breast cancer	9.66e-07	2.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MAPK3—breast cancer	9.65e-07	2.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTEN—breast cancer	9.63e-07	2.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOA2—breast cancer	9.63e-07	2.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA2—breast cancer	9.52e-07	2.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GPX2—breast cancer	9.52e-07	2.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—LEP—breast cancer	9.46e-07	2.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK8—breast cancer	9.42e-07	2.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SULT1A1—breast cancer	9.4e-07	2.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GPX4—breast cancer	9.4e-07	2.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—breast cancer	9.38e-07	2.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KRAS—breast cancer	9.38e-07	2.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CAV1—breast cancer	9.37e-07	2.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—FASN—breast cancer	9.34e-07	2.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—BCHE—breast cancer	9.3e-07	2.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—breast cancer	9.27e-07	2.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	9.22e-07	2.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC5A5—breast cancer	9.18e-07	2.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTA1—breast cancer	9.18e-07	2.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—IDH1—breast cancer	9.18e-07	2.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—COMT—breast cancer	9.13e-07	2.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTP1—breast cancer	9.09e-07	2.14e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NAT2—breast cancer	9.08e-07	2.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HMOX1—breast cancer	8.96e-07	2.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ITPR1—breast cancer	8.94e-07	2.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SRC—breast cancer	8.93e-07	2.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FN1—breast cancer	8.92e-07	2.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC2A1—breast cancer	8.87e-07	2.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NQO1—breast cancer	8.87e-07	2.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NFKBIA—breast cancer	8.82e-07	2.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH1—breast cancer	8.73e-07	2.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VEGFA—breast cancer	8.7e-07	2.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	8.68e-07	2.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP3A4—breast cancer	8.65e-07	2.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STAT3—breast cancer	8.62e-07	2.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—breast cancer	8.62e-07	2.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	8.61e-07	2.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ABCB1—breast cancer	8.6e-07	2.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CG—breast cancer	8.54e-07	2.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—APC—breast cancer	8.54e-07	2.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIT—breast cancer	8.54e-07	2.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—breast cancer	8.54e-07	2.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1B1—breast cancer	8.5e-07	2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMS—breast cancer	8.45e-07	1.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGF—breast cancer	8.44e-07	1.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—breast cancer	8.42e-07	1.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLA2G4A—breast cancer	8.35e-07	1.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NCOR1—breast cancer	8.35e-07	1.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTM1—breast cancer	8.35e-07	1.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HSP90AA1—breast cancer	8.34e-07	1.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—breast cancer	8.33e-07	1.96e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MAPK3—breast cancer	8.23e-07	1.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOA1—breast cancer	8.11e-07	1.91e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—BRAF—breast cancer	8.03e-07	1.89e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—breast cancer	8.01e-07	1.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GPX1—breast cancer	8e-07	1.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP19A1—breast cancer	7.99e-07	1.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—STK11—breast cancer	7.99e-07	1.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TGFB1—breast cancer	7.99e-07	1.88e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—breast cancer	7.97e-07	1.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MED12—breast cancer	7.96e-07	1.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—DPYD—breast cancer	7.96e-07	1.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1A1—breast cancer	7.92e-07	1.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ERCC2—breast cancer	7.85e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALDOA—breast cancer	7.84e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—breast cancer	7.83e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IGF1—breast cancer	7.82e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT2—breast cancer	7.81e-07	1.84e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—IL6—breast cancer	7.63e-07	1.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA3—breast cancer	7.61e-07	1.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A2—breast cancer	7.55e-07	1.77e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CD—breast cancer	7.51e-07	1.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	7.5e-07	1.76e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—COMT—breast cancer	7.43e-07	1.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MAPK3—breast cancer	7.43e-07	1.75e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SERPINE1—breast cancer	7.42e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCG2—breast cancer	7.4e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CPT1A—breast cancer	7.4e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTR—breast cancer	7.4e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KRAS—breast cancer	7.4e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTP1—breast cancer	7.4e-07	1.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—MTHFR—breast cancer	7.38e-07	1.73e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MAPK3—breast cancer	7.32e-07	1.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HMOX1—breast cancer	7.3e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ITPR1—breast cancer	7.28e-07	1.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HPGDS—breast cancer	7.26e-07	1.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—breast cancer	7.23e-07	1.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HBA1—breast cancer	7.21e-07	1.69e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—breast cancer	7.12e-07	1.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOS3—breast cancer	7.09e-07	1.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTT1—breast cancer	7.04e-07	1.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ACHE—breast cancer	7.04e-07	1.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—breast cancer	7.04e-07	1.65e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ABCB1—breast cancer	7e-07	1.64e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMS—breast cancer	6.88e-07	1.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CAV1—breast cancer	6.81e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NCOR1—breast cancer	6.8e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTM1—breast cancer	6.8e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLA2G4A—breast cancer	6.8e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—breast cancer	6.8e-07	1.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MDM2—breast cancer	6.73e-07	1.58e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RAF1—breast cancer	6.7e-07	1.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—RELA—breast cancer	6.67e-07	1.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP17A1—breast cancer	6.66e-07	1.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—breast cancer	6.63e-07	1.56e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS1—breast cancer	6.6e-07	1.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO1—breast cancer	6.6e-07	1.55e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—breast cancer	6.57e-07	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MTOR—breast cancer	6.54e-07	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CB—breast cancer	6.54e-07	1.54e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GPX1—breast cancer	6.51e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—breast cancer	6.51e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.5e-07	1.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2D6—breast cancer	6.47e-07	1.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1A1—breast cancer	6.44e-07	1.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ERCC2—breast cancer	6.39e-07	1.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA2—breast cancer	6.35e-07	1.49e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—breast cancer	6.29e-07	1.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL8—breast cancer	6.29e-07	1.48e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CG—breast cancer	6.2e-07	1.46e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—FASN—breast cancer	6.16e-07	1.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1B—breast cancer	6.14e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—BCHE—breast cancer	6.13e-07	1.44e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC5A5—breast cancer	6.06e-07	1.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—breast cancer	6.02e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—IL6—breast cancer	6.02e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL2—breast cancer	6.01e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—MTHFR—breast cancer	6.01e-07	1.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—breast cancer	5.86e-07	1.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NQO1—breast cancer	5.85e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A1—breast cancer	5.85e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—JUN—breast cancer	5.85e-07	1.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNB1—breast cancer	5.8e-07	1.36e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MMP9—breast cancer	5.69e-07	1.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1A—breast cancer	5.67e-07	1.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTEN—breast cancer	5.65e-07	1.33e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1B1—breast cancer	5.61e-07	1.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—breast cancer	5.55e-07	1.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CAV1—breast cancer	5.54e-07	1.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK8—breast cancer	5.53e-07	1.3e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSP90AA1—breast cancer	5.5e-07	1.29e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CD—breast cancer	5.45e-07	1.28e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALB—breast cancer	5.38e-07	1.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOA1—breast cancer	5.35e-07	1.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	5.29e-07	1.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP19A1—breast cancer	5.27e-07	1.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—STK11—breast cancer	5.27e-07	1.24e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SRC—breast cancer	5.24e-07	1.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NOS3—breast cancer	5.15e-07	1.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VEGFA—breast cancer	5.11e-07	1.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STAT3—breast cancer	5.06e-07	1.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CG—breast cancer	5.05e-07	1.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—breast cancer	5.01e-07	1.18e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—breast cancer	4.94e-07	1.16e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—COMT—breast cancer	4.9e-07	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTP1—breast cancer	4.88e-07	1.15e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MAPK3—breast cancer	4.83e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HMOX1—breast cancer	4.81e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ITPR1—breast cancer	4.8e-07	1.13e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CB—breast cancer	4.75e-07	1.12e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—breast cancer	4.71e-07	1.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—breast cancer	4.7e-07	1.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TGFB1—breast cancer	4.69e-07	1.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCB1—breast cancer	4.62e-07	1.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—breast cancer	4.6e-07	1.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMS—breast cancer	4.54e-07	1.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NCOR1—breast cancer	4.48e-07	1.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLA2G4A—breast cancer	4.48e-07	1.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTM1—breast cancer	4.48e-07	1.05e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CD—breast cancer	4.44e-07	1.04e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALB—breast cancer	4.38e-07	1.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KRAS—breast cancer	4.34e-07	1.02e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GPX1—breast cancer	4.29e-07	1.01e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1A1—breast cancer	4.25e-07	9.98e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ERCC2—breast cancer	4.22e-07	9.9e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NOS3—breast cancer	4.19e-07	9.84e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTEN—breast cancer	4.11e-07	9.65e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—breast cancer	3.99e-07	9.37e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—MTHFR—breast cancer	3.96e-07	9.31e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CB—breast cancer	3.87e-07	9.09e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—breast cancer	3.86e-07	9.06e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—breast cancer	3.83e-07	9e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—breast cancer	3.69e-07	8.67e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CAV1—breast cancer	3.65e-07	8.59e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—IL6—breast cancer	3.53e-07	8.3e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTEN—breast cancer	3.34e-07	7.85e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CG—breast cancer	3.33e-07	7.82e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—breast cancer	3.26e-07	7.65e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CD—breast cancer	2.93e-07	6.87e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—breast cancer	2.9e-07	6.81e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALB—breast cancer	2.89e-07	6.79e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NOS3—breast cancer	2.76e-07	6.49e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CB—breast cancer	2.55e-07	5.99e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—breast cancer	2.53e-07	5.94e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—breast cancer	2.37e-07	5.56e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—breast cancer	2.36e-07	5.54e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTEN—breast cancer	2.2e-07	5.18e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—breast cancer	1.93e-07	4.52e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—breast cancer	1.55e-07	3.65e-06	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—breast cancer	1.27e-07	2.98e-06	CbGpPWpGaD
